Divi's Laboratories (DIVISLAB) Stock Overview
Engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
DIVISLAB Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Divi's Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹6,836.00 |
| 52 Week High | ₹6,968.00 |
| 52 Week Low | ₹5,636.50 |
| Beta | 0.22 |
| 1 Month Change | 2.98% |
| 3 Month Change | 11.76% |
| 1 Year Change | 0.015% |
| 3 Year Change | 85.90% |
| 5 Year Change | 43.69% |
| Change since IPO | 77,471.63% |
Recent News & Updates
Narrative Update • Jul 08
DIVISLAB: Upcoming Board Decisions And Fair Value Assumptions Will Shape Balanced Outlook
Analysts have modestly raised their price target for Divi's Laboratories from ₹6,875 to approximately ₹7,059, citing updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E expectations. What's in the News Divi's Laboratories has scheduled a board meeting on May 23, 2026, at 10:15 Indian Standard Time to review audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Narrative Update • Jun 24
DIVISLAB: Upcoming Board Meeting And Dividend Decision Will Support Bullish Outlook
Analysts have adjusted their fair value estimate for Divi's Laboratories slightly lower from ₹8,812.63 to ₹8,795.18, reflecting small tweaks to assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What’s in the News for Divi's Laboratories A board meeting is scheduled for May 23, 2026, at 10:15 Indian Standard Time to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Narrative Update • Jun 09
DIVISLAB: Upcoming Board Meeting And Dividend Decision Will Support Bullish Outlook
Analysts have raised their fair value estimate for Divi's Laboratories from ₹8,620.23 to ₹8,812.63, reflecting updated assumptions for the discount rate, revenue growth, profit margins and future P/E expectations. What's in the News A board meeting is scheduled for May 23, 2026, at 10:15 IST to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Narrative Update • May 26
DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk
Analysts have lifted Divi's Laboratories price target from ₹5,133.17 to ₹5,333.98, citing updated assumptions on revenue growth, profit margins, and future P/E expectations. What's in the News A board meeting is scheduled for May 23, 2026, at 10:15 Indian Standard Time to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments).Recent updates
Narrative Update • Jul 08
DIVISLAB: Upcoming Board Decisions And Fair Value Assumptions Will Shape Balanced Outlook
Analysts have modestly raised their price target for Divi's Laboratories from ₹6,875 to approximately ₹7,059, citing updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E expectations. What's in the News Divi's Laboratories has scheduled a board meeting on May 23, 2026, at 10:15 Indian Standard Time to review audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Narrative Update • Jun 24
DIVISLAB: Upcoming Board Meeting And Dividend Decision Will Support Bullish Outlook
Analysts have adjusted their fair value estimate for Divi's Laboratories slightly lower from ₹8,812.63 to ₹8,795.18, reflecting small tweaks to assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What’s in the News for Divi's Laboratories A board meeting is scheduled for May 23, 2026, at 10:15 Indian Standard Time to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Narrative Update • Jun 09
DIVISLAB: Upcoming Board Meeting And Dividend Decision Will Support Bullish Outlook
Analysts have raised their fair value estimate for Divi's Laboratories from ₹8,620.23 to ₹8,812.63, reflecting updated assumptions for the discount rate, revenue growth, profit margins and future P/E expectations. What's in the News A board meeting is scheduled for May 23, 2026, at 10:15 IST to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Narrative Update • May 26
DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk
Analysts have lifted Divi's Laboratories price target from ₹5,133.17 to ₹5,333.98, citing updated assumptions on revenue growth, profit margins, and future P/E expectations. What's in the News A board meeting is scheduled for May 23, 2026, at 10:15 Indian Standard Time to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments).Analysis Article • May 26
Divi's Laboratories Limited (NSE:DIVISLAB) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Divi's Laboratories Limited ( NSE:DIVISLAB ) last week reported its latest yearly results, which makes it a good time...Narrative Update • May 04
DIVISLAB: Elevated Future P/E Will Remain A Key Overvaluation Risk
Analysts have trimmed their price target on Divi's Laboratories slightly from ₹5,140 to about ₹5,133, reflecting updated assumptions around discount rates, revenue growth, profit margin, and future P/E expectations. Valuation Changes Fair Value: Trimmed slightly from ₹5,140.00 to about ₹5,133.17 per share.Narrative Update • Apr 20
DIVISLAB: Upcoming Board Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target for Divi's Laboratories slightly, with fair value now seen around ₹8,620 versus about ₹8,554 earlier, reflecting updated assumptions for discount rate, revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled on Feb 11, 2026 to consider and approve unaudited standalone financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).Narrative Update • Apr 05
DIVISLAB: Elevated Future P/E Will Persist Despite Unchanged Fair Value Estimate
Analysts have maintained Divi's Laboratories' fair value estimate at ₹5,140 per share, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together guide the latest price target narrative. What's in the News Board meeting scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Narrative Update • Mar 22
DIVISLAB: Upcoming Board Review And Fair Value Update Signal Constructive Outlook
Analysts have made a small upward adjustment to the fair value estimate for Divi's Laboratories to around ₹6,875, reflecting slightly updated assumptions on the discount rate, revenue growth, profit margins and future P/E. What's in the News Board meeting scheduled on February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Narrative Update • Mar 08
DIVISLAB: Rich Future P/E Will Persist Despite Softer Outlook After Results
Analysts have trimmed their price target on Divi's Laboratories from ₹5,290 to ₹5,140, reflecting updated assumptions around a slightly lower revenue growth outlook, a marginally higher profit margin, a modestly reduced future P/E multiple, and an adjusted discount rate. What's in the News A board meeting is scheduled for February 11, 2026 to review and approve unaudited standalone and consolidated financial results for the quarter ended December 31, 2025 (Key Developments).Narrative Update • Feb 22
DIVISLAB: Upcoming Results Review Will Shape Balanced Long Term Outlook
Narrative Update on Divi's Laboratories The analyst price target for Divi's Laboratories has been adjusted slightly higher from about ₹6,823 to roughly ₹6,870, with analysts pointing to small refinements in assumptions around discount rate, revenue growth, profit margin and future P/E as the drivers of this change. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Narrative Update • Feb 07
DIVISLAB: Upcoming Results Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target on Divi's Laboratories slightly to ₹6,823 from about ₹6,785, citing refreshed assumptions around discount rates, revenue growth, profit margin and future P/E that remain broadly in line with prior views. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Narrative Update • Jan 24
DIVISLAB: Management Changes And Rich Future P/E Will Sustain Excessive Optimism
Analysts now cite slightly higher assumptions on growth, profitability and future P/E in their models for Divi's Laboratories, which feeds into an updated fair value estimate of ₹5,290, compared with the previous ₹5,035.89. What's in the News Board meeting scheduled for November 7, 2025, at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Narrative Update • Jan 10
DIVISLAB: Upcoming Board Review And Management Changes Will Support Bullish Outlook
Analysts have raised their price target for Divi's Laboratories from ₹7,750 to about ₹8,554, citing updated assumptions related to revenue growth, profit margins and future P/E levels in their models. What's in the News Board meeting scheduled on Nov 07, 2025 at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025 (company filing).Analysis Article • Dec 30
Earnings Not Telling The Story For Divi's Laboratories Limited (NSE:DIVISLAB)
Divi's Laboratories Limited's ( NSE:DIVISLAB ) price-to-earnings (or "P/E") ratio of 68.3x might make it look like a...Narrative Update • Dec 25
DIVISLAB: Rising Profitability Expectations Will Mask Moderating Revenue And Justify Excessive Optimism
Analysts have raised their price target for Divi's Laboratories from ₹4,756 to ₹5,036, citing expectations of stronger profitability and a slightly richer future valuation multiple, despite moderating revenue growth assumptions. What's in the News Board meeting scheduled for November 7, 2025 at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Narrative Update • Dec 11
DIVISLAB: Upcoming Board Meeting And Leadership Review Will Shape Fair Outlook
Analysts have nudged their price target for Divi's Laboratories slightly higher, reflecting marginal improvements in discount rate assumptions and long term growth expectations that together support a fair value estimate of ₹6,785.10 per share. What's in the News Board meeting scheduled for November 7, 2025, at 10:30 IST to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Analysis Article • Dec 09
Divi's Laboratories (NSE:DIVISLAB) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Narrative Update • Nov 27
DIVISLAB: Upcoming Board Decisions And Modest Earnings Improvements Will Shape Outlook
Analysts have raised their fair value estimate for Divi's Laboratories from ₹6,433 to ₹6,785, citing modest improvements in revenue growth and profit margin expectations. What's in the News A board meeting is scheduled for November 7, 2025, at 10:30 IST to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments).Analysis Article • Nov 15
Investors Shouldn't Be Too Comfortable With Divi's Laboratories' (NSE:DIVISLAB) Earnings
Despite posting some strong earnings, the market for Divi's Laboratories Limited's ( NSE:DIVISLAB ) stock hasn't moved...Analysis Article • Nov 11
Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Divi's Laboratories Limited ( NSE:DIVISLAB ) just released its latest interim results and things are looking bullish...Narrative Update • Nov 08
DIVISLAB: Upcoming Board Decisions And Modest Earnings Improvements Will Shape Outlook
Analysts have modestly increased their price target for Divi's Laboratories from ₹6,363 to ₹6,433, citing slight improvements in projected revenue growth and profit margins as the underlying factors. What's in the News Upcoming Board Meeting scheduled for November 7, 2025, at 10:30 AM IST.Analysis Article • Sep 06
Divi's Laboratories Limited's (NSE:DIVISLAB) Share Price Could Signal Some Risk
With a price-to-earnings (or "P/E") ratio of 69.2x Divi's Laboratories Limited ( NSE:DIVISLAB ) may be sending very...Narrative Update • Sep 05
Custom Synthesis And Capacity Expansion Will Unlock Global Demand
With both the consensus price target and future P/E ratio for Divi's Laboratories remaining virtually unchanged, analysts signal stable valuation expectations, resulting in a steady fair value assessment at ₹6363. What's in the News Board meeting scheduled to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2025.Analysis Article • Aug 10
Divi's Laboratories Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
NSEI:DIVISLAB 1 Year Share Price vs Fair Value Explore Divi's Laboratories's Fair Values from the Community and select...Analysis Article • Aug 05
Most Shareholders Will Probably Agree With Divi's Laboratories Limited's (NSE:DIVISLAB) CEO Compensation
Key Insights Divi's Laboratories' Annual General Meeting to take place on 11th of August CEO Kiran Divi's total...Analysis Article • Jul 17
Here's What Analysts Are Forecasting For Divi's Laboratories Limited (NSE:DIVISLAB) After Its Yearly Results
Divi's Laboratories Limited ( NSE:DIVISLAB ) shareholders are probably feeling a little disappointed, since its shares...
New Narrative • Nov 10
Tactical Expansions And Innovation Could Offset Generic Pricing Pressures And Boost Profitability
Strategic investments in peptide synthesis and greenfield expansion enhance future revenue potential through capacity and product line growth.Shareholder Returns
| DIVISLAB | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | 1.2% | 0.5% | -0.9% |
| 1Y | 0.01% | -0.9% | -2.1% |
Return vs Industry: DIVISLAB matched the Indian Life Sciences industry which returned -0.9% over the past year.
Return vs Market: DIVISLAB exceeded the Indian Market which returned -2.1% over the past year.
Price Volatility
| DIVISLAB volatility | |
|---|---|
| DIVISLAB Average Weekly Movement | 2.7% |
| Life Sciences Industry Average Movement | 5.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 3.9% |
Stable Share Price: DIVISLAB has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: DIVISLAB's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 10,542 | Kiran Divi | www.divislabs.com |
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as lutein and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products.
Divi's Laboratories Limited Fundamentals Summary
| DIVISLAB fundamental statistics | |
|---|---|
| Market cap | ₹1.81t |
| Earnings (TTM) | ₹25.68b |
| Revenue (TTM) | ₹105.60b |
70.7x
P/E Ratio17.2x
P/S RatioIs DIVISLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DIVISLAB income statement (TTM) | |
|---|---|
| Revenue | ₹105.60b |
| Cost of Revenue | ₹40.93b |
| Gross Profit | ₹64.67b |
| Other Expenses | ₹38.99b |
| Earnings | ₹25.68b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 96.73 |
| Gross Margin | 61.24% |
| Net Profit Margin | 24.32% |
| Debt/Equity Ratio | 0% |
How did DIVISLAB perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield31%
Payout RatioDoes DIVISLAB pay a reliable dividends?
See DIVISLAB dividend history and benchmarks| Divi's Laboratories dividend dates | |
|---|---|
| Ex Dividend Date | Jul 24 2026 |
| Dividend Pay Date | Sep 09 2026 |
| Days until Ex dividend | 13 days |
| Days until Dividend pay date | 60 days |
Does DIVISLAB pay a reliable dividends?
See DIVISLAB dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/10 17:10 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Divi's Laboratories Limited is covered by 49 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| Pranav Chawla | Ambit Capital |